# ET 140202 -T Cell Combined With TAE or Sorafenib in the Treatment of Liver Cancer

> **NCT03965546** · EARLY_PHASE1 · UNKNOWN · sponsor: **First Affiliated Hospital Xi'an Jiaotong University** · enrollment: 27 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Liver Cancer
- Liver Neoplasms
- Metastatic Liver Cancer

## Interventions

- **COMBINATION_PRODUCT:** Sorafenib combined with ET140202-T cell
- **COMBINATION_PRODUCT:** TAE combined with ET140202-T cell
- **BIOLOGICAL:** ET140202-T cell

## Key facts

- **NCT ID:** NCT03965546
- **Lead sponsor:** First Affiliated Hospital Xi'an Jiaotong University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-05-30
- **Primary completion:** 2021-06
- **Final completion:** 2022-06
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2019-08-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03965546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03965546, "ET 140202 -T Cell Combined With TAE or Sorafenib in the Treatment of Liver Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03965546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*